Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by Dana-Farber Cancer Institute
Brigham and Women's Hospital
Children's Hospital Boston
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Maureen Okam, MD, MPH, Dana-Farber Cancer Institute Identifier:
First received: October 20, 2009
Last updated: April 24, 2013
Last verified: April 2013

October 20, 2009
April 24, 2013
October 2009
July 2013   (final data collection date for primary outcome measure)
  • To determine the efficacy of vorinostat when administered orally in inducing a 4% absolute increase or a 100% increase in fetal hemoglobin levels in subjects with severe sickle cell disease who have failed prior therapy. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To characterize the safety and tolerability of vorinostat in subjects with sickle cell disease. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01000155 on Archive Site
  • To assess the effect of vorinostat on F-cell levels. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine the changes is y-globin, B-globin and E-globin RNA levels during treatment with vorinostat. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To describe the dose-response characteristics of vorinostat in inducing fetal hemoglobin in sickle cell disease [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Not Benefitted From Prior Therapy

Sickle Cell Disease (SCD) is a hereditary anemia that causes the red blood cells to change their shape from a round and doughnut-like shape to a half-moon/crescent, or sickled shape. People who have SCD have a different type of hemoglobin (protein that carries oxygen). This different type of hemoglobin makes the red blood cells change into a crescent shape under certain conditions. Sickle-shaped cells are a problem because they often get stuck in the blood vessels blocking the flow of blood and can cause inflammation and injury to important areas of the body. All babies are born with hemoglobin called fetal hemoglobin (HbF). Soon after birth, HbF production slows down and another hemoglobin called adult hemoglobin (HbA) is made. Clinical studies have shown that increasing the amount of HbF in the blood may prevent sickling of the red blood cells. Vorinostat has been used in the treatment of cancers and in other research studies and information from those suggests that it may help treat SCD by increasing the amount of HbF in the blood. The purpose of this research study is to determine the effectiveness and safety of vorinostat when used to treat SCD.

  • Since we are looking for the highest dose of vorinostat that can be administered safely without severe or unmanageable side effects in participants who have SCD, the participants dose may change while they are enrolled in the study.
  • Participants will receive an initial dose of vorinostat for the first cycle (or 4 weeks). If they tolerate this dose, they will receive a higher dose for the second cycle. The dose will be increased a 2nd time if they tolerate the dose of the second cycle. Participants will continue on that highest dose for as long as they can tolerate it, or, for a maximum of 4 cycles. The maximum dose participants could receive is 400mg a day, 3 times a week.
  • Participants will be given a study drug diary for each study cycle to record each time they take vorinostat and indicate if they have any changes in their health or in medications they are taking.
  • During the study participants will come to the clinic for visits with the study team and may have some of the following tests: physical examination, EKG, blood tests, urine tests and echocardiogram.
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Sickle Cell Disease
  • Sickle Cell Anemia
Drug: vorinostat
Taken orally once-a-day on for 3 consecutive days, every week. (For example, Mon-Tues-Wed, Tues-Wed-Thurs or Wed-Thurs-Fri)
Other Name: SAHA
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2014
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of sickle cell disease
  • Clinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease
  • Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea
  • 18 years of age or older
  • Hematologic laboratory values as outlined in the protocol
  • Non-hematologic laboratory values as outlined in the protocol
  • Must agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter
  • Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment
  • Women of child-bearing potential and men must agree to use 2 forms of adequate contraception prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Subjects with hemoglobin SC or SB+ thalassemia
  • Subjects on chronic transfusion program
  • Subjects who have received RBC transfusions cannot have >15% adult hemoglobin
  • Known positive status for HIV, active hepatitis B or hepatitis C
  • Pregnant or breast feeding women
  • Individuals with a history of malignancy are ineligible except for the following circumstances. Individuals with a history of malignancy are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancer are eligible if diagnosed and adequately treated within the past 5 years: cervical or breast cancer in situ, and basal cell or squamous cell carcinoma of the skin
  • Subjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk
  • Subjects with unresolved infections
  • Severe or uncontrolled medical conditions that could compromise study participation
  • Subjects on fetal hemoglobin inducing agents
  • Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy
  • Known allergic reaction to a histone deacetylase inhibitor
  • Subjects who have received valproic acid for treatment of epilepsy within 30 days of enrollment
  • Subjects who have received any HDAC inhibitors other than valproic acid
18 Years and older
Contact: Maureen Okam, MD, MPH 617-732-5048
Contact: Rachel Wentz 617-278-0377
United States
Maureen Okam, MD, MPH, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Children's Hospital Boston
  • Merck Sharp & Dohme Corp.
Principal Investigator: Maureen Okam, MD, MPH Brigham and Women's Hospital
Dana-Farber Cancer Institute
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP